Coherus Oncology Statistics
Total Valuation
CHRS has a market cap or net worth of $59.82 million. The enterprise value is $45.74 million.
Important Dates
The last earnings date was Monday, November 9, 2026, after market close.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CHRS has 154.54 million shares outstanding. The number of shares has increased by 22.26% in one year.
| Current Share Class | 154.54M |
| Shares Outstanding | 154.54M |
| Shares Change (YoY) | +22.26% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 4.25% |
| Owned by Institutions (%) | 48.55% |
| Float | 147.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.10 |
| Forward PS | 0.77 |
| PB Ratio | 2.51 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.51, with a Debt / Equity ratio of 2.75.
| Current Ratio | 1.51 |
| Quick Ratio | 1.29 |
| Debt / Equity | 2.75 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.24 |
Financial Efficiency
Return on equity (ROE) is -275.17% and return on invested capital (ROIC) is -1,392.96%.
| Return on Equity (ROE) | -275.17% |
| Return on Assets (ROA) | -26.43% |
| Return on Invested Capital (ROIC) | -1,392.96% |
| Return on Capital Employed (ROCE) | -152.31% |
| Weighted Average Cost of Capital (WACC) | 10.48% |
| Revenue Per Employee | $369,924 |
| Profits Per Employee | -$937,483 |
| Employee Count | 145 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 4.71 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.01% in the last 52 weeks. The beta is 1.05, so CHRS's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | -68.01% |
| 50-Day Moving Average | 0.99 |
| 200-Day Moving Average | 1.43 |
| Relative Strength Index (RSI) | 23.71 |
| Average Volume (20 Days) | 2,792,301 |
Short Selling Information
The latest short interest is 12.71 million, so 8.23% of the outstanding shares have been sold short.
| Short Interest | 12.71M |
| Short Previous Month | 12.45M |
| Short % of Shares Out | 8.23% |
| Short % of Float | 8.59% |
| Short Ratio (days to cover) | 8.04 |
Income Statement
In the last 12 months, CHRS had revenue of $53.64 million and -$135.94 million in losses. Loss per share was -$0.96.
| Revenue | 53.64M |
| Gross Profit | 37.45M |
| Operating Income | -145.41M |
| Pretax Income | -155.50M |
| Net Income | -135.94M |
| EBITDA | -141.92M |
| EBIT | -145.41M |
| Loss Per Share | -$0.96 |
Full Income Statement Balance Sheet
The company has $83.63 million in cash and $69.55 million in debt, with a net cash position of $14.08 million or $0.09 per share.
| Cash & Cash Equivalents | 83.63M |
| Total Debt | 69.55M |
| Net Cash | 14.08M |
| Net Cash Per Share | $0.09 |
| Equity (Book Value) | 25.25M |
| Book Value Per Share | 0.16 |
| Working Capital | 38.49M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -173.71M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 3.49M |
| Net Borrowing | 11.88M |
| Free Cash Flow | -173.71M |
| FCF Per Share | -$1.12 |
Full Cash Flow Statement Margins
Gross margin is 69.81%, with operating and profit margins of -271.09% and -253.43%.
| Gross Margin | 69.81% |
| Operating Margin | -271.09% |
| Pretax Margin | -289.91% |
| Profit Margin | -253.43% |
| EBITDA Margin | -264.58% |
| EBIT Margin | -271.09% |
| FCF Margin | n/a |
Dividends & Yields
CHRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.26% |
| Shareholder Yield | -22.26% |
| Earnings Yield | -247.82% |
| FCF Yield | -294.18% |
Analyst Forecast
The average price target for CHRS is $7.25, which is 1,772.90% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.25 |
| Price Target Difference | 1,772.90% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 49.55% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CHRS has an Altman Z-Score of -13.44 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.44 |
| Piotroski F-Score | 3 |